Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with pharmacokinetic tables, trial endpoints, and FDA correspondence can drain an entire afternoon. Lipocine’s disclosures are doubly challenging because each 10-K details evolving clinical data for TLANDO and oral brexanolone, while every 8-K flags material events like Phase 2 topline results. If you have ever wondered, “How do I locate Lipocine insider trading Form 4 transactions before the next catalyst?” this page turns that frustration into clarity.
Stock Titan’s AI-powered analysis breaks down every Lipocine SEC filing—10-Qs, 10-Ks, S-1s, and real-time Form 4s—into concise summaries, risk matrices, and searchable highlights. You’ll see Lipocine quarterly earnings report 10-Q filing metrics side-by-side with liquidity runway charts, receive Form 4 insider transactions real-time alerts, and get plain-English answers to questions like “Why did Lipocine file an 8-K on trial enrollment?” or “What does the latest proxy statement executive compensation reveal?” No more scrolling through hundreds of pages; understanding Lipocine SEC documents with AI takes minutes.
Whether you’re tracking Lipocine executive stock transactions Form 4, looking for Lipocine earnings report filing analysis before modeling cash burn, or need a Lipocine annual report 10-K simplified view of pipeline milestones, you’ll find everything here. Our coverage refreshes the moment an EDGAR stamp appears, so Lipocine 8-K material events explained updates land in your dashboard instantly. Use the insights to monitor FDA timelines, compare quarter-over-quarter R&D spend, or spot insider sentiment shifts—practical intelligence that helps you act, not just read.
Lipocine Inc. (LPCN) – Q2 2025 10-Q snapshot
For the quarter ended 30 Jun 2025, revenue jumped to $0.623 M (vs $0.090 M LY) on a one-time $0.5 M license payment from newly signed partners, offsetting lower royalties. Operating expenses fell 10% YoY to $3.0 M, led by a 41% drop in G&A, but R&D rose 14% to support LPCN 1154 and other pipeline programs. Net loss narrowed to $2.21 M (-$0.41 EPS) from -$3.07 M (-$0.57 EPS).
Six-month results were weaker: revenue fell 91% YoY to $0.717 M as the prior-year period contained a $7.5 M Verity up-front; net loss swung to $4.07 M (-$0.76 EPS) from a $0.45 M profit. Operating cash burn was $3.9 M; cash & treasury bills ended at $18.6 M (cash $6.0 M, securities $11.9 M) versus $22.5 M 12/31/24. Management projects liquidity through at least Aug 2026 but continues to access an ATM facility (23,739 shares sold for $0.08 M during Q2).
- Total liabilities remain low at $1.45 M; equity fell to $17.1 M.
- New Aché license (Brazil) plus earlier SPC (South Korea) and Pharmalink (GCC) deals expand TLANDO ex-US footprint; up to $259 M in contingent milestones remain unrealized.
- Authorized shares cut to 75 M; 5.42 M shares outstanding.
- No warrants outstanding after 2019/2020 series expired.
Outlook: Near-term revenue hinges on additional license milestones and TLANDO royalties; continued pipeline spend and limited cash generation imply further equity or partnership funding before 2026.
On 9 July 2025 Lipocine Inc. (NASDAQ: LPCN) filed a Form 8-K under Item 8.01 – Other Events. The sole disclosure is that the company hosted a virtual key-opinion-leader (KOL) event focused on LPCN 1154 (BRLIZIO™) as a potential treatment for postpartum depression. A webcast link and slide deck are available on the corporate website, and the materials have been furnished as Exhibit 99.1.
Under Item 9.01 the filing lists Exhibit 104 (Inline XBRL cover page). No financial metrics, clinical trial results, or transactional details accompany the notice. The document is signed by President & CEO Mahesh V. Patel.
This 8-K signals continued development and external engagement around LPCN 1154 but provides no new quantitative data likely to affect near-term valuation.
Lipocine (NASDAQ:LPCN) filed an 8-K announcing that the first patient has been dosed in its Phase 3 clinical trial of LPCN 1154 for postpartum depression. The disclosure, furnished under Item 8.01 with the press release attached as Exhibit 99.1, marks the transition of LPCN 1154 into late-stage development—an essential step toward potential NDA submission and commercialization. No changes to financial guidance, funding, or corporate strategy were reported, and Items 2.02, 5.02 or other sections were not included. While the filing contains no revenue figures, the milestone may accelerate future catalysts such as data read-outs, regulatory meetings and partnership discussions that could materially influence valuation.
FAQ
What is the current stock price of Lipocine (LPCN)?
What is the market cap of Lipocine (LPCN)?
